Long-chain polyunsaturated fatty acid supplementation increases levels in red blood cells and reduces the prevalence and severity of squamous gastric ulcers in exercised Thoroughbreds.

OBJECTIVE: To assess the relationship between plasma and RBC fatty acid composition and incidence and severity of squamous gastric ulcers when altered by short-chain (SC) or long-chain (LC) polyunsaturated fatty acid (PUFA) supplementation. ANIMALS: 13 fit Thoroughbred horses in training. PROCEDURES: Horses were evaluated by gastroscopy for squamous ulcer score, gastric pH, and blood fatty acid composition prior to supplementation (UNSUPP) and after 3 months of supplementation with a corn-flax oil blend of alpha-linolenic acid and linoleic acid (SC-PUFA) or a gamma-linolenic acid (GLA)-fish oil blend of GLA, eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA; LC-PUFA) in a crossover design. Prior to gastroscopy and blood collection, horses performed a 4,600-m standardized exercise test on the racetrack as a stressor. RESULTS: Three months of supplementation with LC-PUFAs increased RBC levels of GLA, dihomo-gamma-linolenic acid (DGLA), arachidonic acid (AA), EPA, and DHA, and reduced severe ulcer prevalence (38% UNSUPP vs 8% LC-PUFA with a severe ulcer score of grade 3 to 4). Short-chain PUFA supplementation did not effectively elevate RBC GLA, DGLA, AA, EPA, or DHA and severe ulcer incidence was not different (38% UNSUPP vs 23% SC-PUFA with a severe ulcer score of grade 3 to 4). Lower levels of RBC GLA, DGLA, AA, and EPA correlated with severe squamous gastric ulceration (grade 3 to 4). CLINICAL RELEVANCE: Equine gastric ulcer syndrome is prevalent in high-performance horses and is a concern to owners and trainers. Long-chain PUFA supplementation increased levels of GLA, DGLA, AA, EPA, and DHA, unlike SC-PUFA supplementation, and was associated positively with prevention or resolution of severe squamous gastric ulceration. Further studies are needed to evaluate different management styles and exercise intensities.

Omeprazole Reduces Calcium Digestibility in Thoroughbred Horses.

Proton pump inhibitors such as omeprazole reduce nutrient digestibility in humans. This study determined the effect of omeprazole on the digestibility of diets containing limestone or marine-derived calcium (BMC) and to assess changes in blood parameters associated with gastric acid production and calcium status in horses. Thoroughbreds were used to evaluate the digestibility of diets containing different calcium sources with or without omeprazole over four 21-day periods. Each 21-day period had a 15-day diet adaptation phase followed by a 6-day collection phase, consisting of a 5-day total fecal collection period and a final day for gastroscopy and blood sampling. Horses were fed the same diet with either 60 g/d BMC or 50 g/d limestone, so the total diet provided ∼45 g calcium. Horses on omeprazole were given GastroGard once daily for the final 14 day of each 21-day period, which supplied 3.91 ± 0.17 mg/kg BW/d of omeprazole. On day 21, blood samples were taken and gastric fluid pH was measured 8 hour after omeprazole administration. Omeprazole had a profound effect on gastric fluid pH in omeprazole-treated horses compared with nontreated horses. Serum gastrin doubled in omeprazole-treated horses compared with nontreated horses. Omeprazole and calcium source did not affect digestibility of phosphorus, magnesium, potassium, sodium, iron, copper, zinc, or manganese but did affect calcium digestibility. Omeprazole reduced apparent calcium digestibility from 52.0% to 41.4% in limestone and from 55.1% to 46.5% in BMC, equalling a 20.3% and 15.6% decrease in calcium digestibility in the limestone and BMC, respectively. Mineral source had a significant effect on calcium digestibility with BMC at 50.8% and limestone at 46.7%.